Seres reports SER-155 irEC trial data as it seeks partners and cuts facility costs
Seres said 80% of patients in an MSK-run trial of SER-155 hit the day-15 response endpoint, while the company works to fund its allo-HCT and IBD programs.
SEC filing
Latest
3 stories
Wednesday, August 5
Tuesday, August 4
Seres Therapeutics issues shares to former landlord to settle lease termination debt
Seres registered 103,520 shares for BMR-Sidney at $4.83 each, worth $500,001.60, as partial payment for ending its Sidney Research Campus lease.
SEC filing
Seres Therapeutics ends part of Cambridge lease, pays landlord in cash and stock
The company terminated roughly 21,295 square feet of its Sidney Street facility and shortened the remaining lease term to cut ongoing facilities costs.
SEC filing